Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Letrozole for Endometrioma Recurrence Prevention
NCT05487092Recruiting
- Sponsor
- The University of Hong Kong
- Start
- Dec 2022
- Primary completion
- Dec 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, double-blind trial in endometrioma comparing Letrozole + COC with Placebo + COC (2 arms). Primary endpoint: Recurrence of endometrioma at 12 months. Started Dec 2022; status: recruiting.
02
Drugs
letrozole
03
Conditions
endometrioma
Beyond the preview
Go deeper on NCT05487092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05487092.